Invex Therapeutics (ASX:IXC) Interest Received: A$0.18 Mil (TTM As of Dec. 2025)


What is Invex Therapeutics Interest Received?

Invex Therapeutics ASX:IXC Interest Received is A$0.18 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Interest Received for the six months ended in Dec. 2025 was A$0.07 Mil.

Invex Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.18 Mil.

Invex Therapeutics Interest Received Related Terms

Invex Therapeutics Interest Received Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Interest Received Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
Get a 7-Day Free Trial 0.16 0.08 0.80 0.49 0.23

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.12 0.12 0.12 0.07

Invex Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of A$0.18 Mil mean?
Invex Therapeutics (ASX:IXC) has a Interest Received of A$0.18 Mil as of Dec. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Interest Received too high?
Invex Therapeutics' current Interest Received is A$0.18 Mil.
How does Invex Therapeutics' Interest Received compare to VRTX and REGN?
Invex Therapeutics' Interest Received of A$0.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Biotechnology company?
A good Interest Received depends on the Biotechnology industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Interest Received is A$0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Interest Received of A$0.18 Mil. The current Interest Received is A$0.18 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Interest Received is A$0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.